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an extremely poor prognosis, and most patients initially are
or rapidly become unresponsive to platinum-based chemo-
therapy.MicroRNA-31 (miR-31) is encodedonagenomic fragile
site, 9p21.3, which is reportedly lost in many MPM tumors.
Based on previous ﬁndings in a variety of other cancers, we
hypothesized that miR-31 alters chemosensitivity and that
miR-31 reconstitution may inﬂuence sensitivity to chemothera-
peutics in MPM. Reintroduction of miR-31 into miR-31 null
NCI-H2452 cells signiﬁcantly enhanced clonogenic resistance
to cisplatin and carboplatin. Although miR-31 re-expression
increased chemoresistance, paradoxically, a higher relative intra-
cellular accumulation of platinum was detected. This was
coupled to a signiﬁcantly decreased intranuclear concentration
of platinum. Linked with a downregulation of OCT1, a bipoten-
tial transcriptional regulator with multiple miR-31 target bind-
ing sites, we subsequently identiﬁed an indirect miR-31-medi-
ated upregulation of ABCB9, a transporter associated with
drug accumulation in lysosomes, and increased uptake of plat-
inum to lysosomes. However, when overexpressed directly,
ABCB9 promoted cellular chemosensitivity, suggesting that
miR-31 promotes chemoresistance largely via an ABCB9-inde-
pendent mechanism. Overall, our data suggest that miR-31
loss from MPM tumors promotes chemosensitivity and may be
prognostically beneﬁcial in the context of therapeutic sensitivity.Received 23 November 2016; accepted 3 July 2017;
http://dx.doi.org/10.1016/j.omtn.2017.07.001.
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Malignant mesothelioma (MM) is a relatively rare, aggressive tumor
that originates in the cells that compose the mesothelial surface of
coelomic cavities of the body. The pleural form of malignant meso-
thelioma (MPM) is the most frequent presentation of the disease,
with other areas of the body contributing to approximately 22% of
MM cases.1–3 The primary agent for MPM pathogenesis is exposure
to asbestos ﬁbers.4 Unfortunately, the disease has a long latency
period with onset between 20 and 40 years after exposure. Patients
diagnosed with MPM are faced with an extremely poor prognosis
(median survival < 9 months after diagnosis), which is mainly attrib-
uted to poor responses to platinum-based chemotherapeutics, the
primary treatment modality for MPM, alongside the anti-folate pe-
metrexed.5,6 Acquisition and maintenance of chemotherapy-resistant
phenotypes remain both clinical and scientiﬁc challenges in MPM.
Therefore, investigation into the affected molecular pathways andMolecular Thera
This is an open access article under thow these are regulated is of high importance in improving the prog-
nosis and survival times in patients who have limited options.
MicroRNAs (miRNAs) are small, non-coding RNAs approximately
18–22 nucleotides in length that function to regulate gene expression
at the post-transcriptional level7 (comprehensively reviewed in
Lynam-Lennon et al.8 and Maher et al.9). miRNAs are involved in
all fundamental biological pathways and cellular processes, so it is
not surprising that miRNA dysfunction is considered instrumental
in the acquisition of the hallmarks of cancer.10 miRNAs are novel
therapeutic targets and promising biomarkers with potential applica-
tions in diagnosis, prognosis, tumor staging, predicting patient
response to treatment, and determining developmental lineages and
clinical subtypes.11–14
The chromosomal fragile site at 9p21.3 is often lost in mesotheliomas
and encodes p16, a potent tumor suppressor and cell-cycle regu-
lator.15,16 In addition, the fragile site encodes microRNA-31
(miR-31), making this miRNA one of the most commonly deleted
in MPM. Ivanov et al.17 previously reported a downregulation of
miR-31 due to deletions on chromosome 9p21.3 in approximately
54% of tumors from MPM patients. It was observed that the reconsti-
tution of miR-31 inhibited factors involved in cell-cycle progression
and DNA repair, in line with our previous ﬁndings in esophageal
adenocarcinoma.18 In contrast, miR-31 downregulation has been
correlated with increased long-term survival in patients, with the prop-
osition that miR-31 can act as an oncogenic microRNA in MPM.19
The research indicated a signiﬁcant negative relationship between
miR-31 expression and survival time in an aggressive sarcomatoid
MPM patient cohort.19 Studies have indicated, as in other cancers,20,21
that miRNAs play pivotal roles in the onset and progression of MPM,
making them putative targets for therapy or markers of prognosis.
Given our previous ﬁnding that miR-31 regulates DNA repair gene
expression in esophageal adenocarcinoma,18 which has a similar eti-
ology to MPM, and considering that there are supportive studies inpy: Nucleic Acids Vol. 8 September 2017 ª 2017 The Authors. 317
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Molecular Therapy: Nucleic AcidsMPM,17 we hypothesized that miR-31 loss may promote resistance
to chemotherapy via alterations in DNA damage and repair.
Surprisingly, upon re-expression of miR-31 in an otherwise-deﬁcient
cell line, we observed increased resistance to cis-dichlorodiaminepla-
tinum(II) (cisplatin), with the converse observed upon miR-31 sup-
pression in an endogenously expressing MPM cell line, P31. We
determined a signiﬁcantly decreased platinum content within the
intranuclear region of miR-31-expressing cells and found DNA dam-
age induction to be lower upon miR-31 reintroduction. Finally, a
potential negative regulator of transcription with multiple miR-31
binding sites in the 30 UTR region, OCT1,22 may promote the upre-
gulation of lysosomal drug transport via ABCB9, implying the seques-
tration of cisplatin into intracellular compartments, whereby it
cannot access the nuclear compartment to mediate its primary
cytotoxic effects.23,24 This mechanism may be used to evade DNA
damage, promoting cellular resistance to platinum-containing che-
motherapeutics. However, although the drug transporter ABCB9
was upregulated with miR-31 reintroduction, when ABCB9 was inde-
pendently overexpressed in the miR-31 null NCI-H2452 cell line,
there was a marked increase in sensitivity to cisplatin treatment.
While this demonstrates a functional role for ABCB9 in modulating
chemosensitivity, the data ultimately support that miR-31 promotes
chemoresistance in MPM via an ABCB9-independent mechanism.
Our data suggest that while deletions in chromosome 9p21.3 may
be associated with an overall poor prognosis, the speciﬁc loss of
miR-31 from this region may not contribute to the chemoresistance
observed in MPM patients.
RESULTS
miR-31 Modulates Sensitivity to Platinum-Based Chemotherapy
Because miR-31 has previously been associated with resistance to
therapy, the effect of either reintroducing or suppressing miR-31
in MPM cells was assessed. The miR-31 null epithelioid NCI-
H2452 cell line was stably transfected with either miR-VC
(microRNA vector control) or miR-31 expression plasmids, while
epithelioid P31 cells expressing endogenous miR-31 were stably
transfected with suppression plasmids Zip-miR-VC or Zip-miR-31
(Figures S1 and S2). To establish whether miR-31 modulation
altered the overall sensitivity of cells treated with platinum-based
chemotherapy, the clonogenic assay was applied using the appro-
priate inhibitory concentration 50 (IC50) doses (Figure S3). The
established IC50 doses were in line with previously published doses
for these cell lines.25–27 Higher doses of chemotherapies were
used in further experiments to facilitate the study of mechanistic
properties. To ascertain overall alterations in survival with treat-
ment, the gold standard clonogenic assay was again used. There
was a signiﬁcant increase in the surviving fraction of 9.6 ± 1.6 in
response to miR-31 reintroduction in NCI-H2452 with cisplatin
treatment and a 19.3 ± 0.2 increase in the surviving fraction with
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (carbopla-
tin) treatment. Furthermore, there was an 8.4 ± 0.2 signiﬁcant in-
crease in the surviving fraction with miR-31 suppression, illustrating
sensitivity to cisplatin upon suppression of miR-31 in the P31 cell
line (Figure 1A). However, the silencing of miR-31 in the P31 cell318 Molecular Therapy: Nucleic Acids Vol. 8 September 2017line led to no signiﬁcant difference in the surviving fraction when
treated with carboplatin.
Following from the observation that reintroduction of miR-31
increased clonogenic survival in NCI-H2452 and decreased survival
in the miR-31-suppressed P31 cell lines, a cumulative cell count
was undertaken to ﬁrst determine whether miR-31 alone, without
the inﬂuence of chemotherapy, would alter proliferation, as previ-
ously noted in Ivanov et al.17 In addition, the cumulative cell count
attempted to ascertain at what time point miR-31 might inﬂuence
proliferation. miR-31 manipulation without the inﬂuence of chemo-
therapy produced no signiﬁcant change in proliferation rate; the cells
only responded differently after cisplatin treatment, suggesting
miR-31 plays an active role in the response to chemotherapy. A
disparity in the ability of the miR-31-overexpressing NCI-H2452 cells
to respond to cisplatin was observed, as evident in the comparison be-
tween treated groups in Figure 1B. A signiﬁcant change in prolifera-
tion of NCI-H2452 miR-31 occurred only 9 days after treatment with
cisplatin, whereas the vector control equivalent was signiﬁcantly
affected by cisplatin 3 days after treatment. Basal proliferation re-
mained unaltered bymiR-31 status, suggesting that with miR-31, cells
had a delay in cytotoxic response (Figure 1B). While miR-31 modu-
lates chemosensitivity, in order to assess whether the alterations in
resistance were attributed speciﬁcally to chemotherapy, radiosensi-
tivity was analyzed, which remained unaltered by miR-31 status in
MPM cells (Figures S4 and S5). Although chemotherapy and radio-
therapy both target DNA, the two modalities have considerably
different mechanisms of action, indicating a chemotherapy-speciﬁc
enhancement of resistance, most likely attributed to a mechanism
that is chemotherapy limited.
miR-31 Alters Intracellular Distribution of Cisplatin in MPM
To begin to establish a potential mechanism underpinning miR-31-
mediated chemoresistance, the inﬂuence of miR-31 on DNA dam-
age induction was assessed via levels of phospho-histone H2A.X
(gH2A.X), which is phosphorylated on serine 139 in response to
DNA damage.28 NCI-H2452 miR-31 cells displayed a reduction
in gH2A.X levels, whereas P31 Zip-miR-31 cells demonstrated
an increase in gH2A.X, both in response to cisplatin and carbopla-
tin treatment (Figure 2). This suggests a role for miR-31 in either
antagonizing DNA damage induction or promoting repair. The
alteration to gH2A.X was not limited to platinum-based therapy;
a similar trend was apparent upon treatment with 5-ﬂuorouracil
(5-FU), which has a different mechanism of action but still relies
upon active transport into the intracellular environment (Fig-
ure S6). Differential activity of gH2A.X was also observed in
response to DMSO treatment with miR-31 reintroduction. To
determine whether this was due to gross alterations in DNA dam-
age and repair pathways, levels of phospho-53bp1 were analyzed
after irradiation treatment (Figure S5). No change was observed
in radiation-treated groups, suggesting reliance upon altered trans-
port and accumulation within the intracellular environment in
miR-31-positive cells, rather than alterations in DNA damage in-
duction or repair.
Figure 1. miR-31 Modulation in MPM Cells Alters
Cellular Sensitivity in Response to Platinum-Based
Chemotherapy Treatment
(A) Clonogenic analysis of miR-31 reintroduction illustrated a
significant difference (p = 0.0028) between the surviving
fractions of miR-VC-transfected cells treated with 1 mM
cisplatin (IC50 dose) for 24 hr and the miR-31-transfected
equivalent (n = 7). Furthermore, there is a significant differ-
ence (p = 0.0084) between the surviving fractions of P31 Zip-
miR-VC-transfected cells treated with 2 mM cisplatin (IC50
dose) and the Zip-miR-31 equivalent (n = 3). miR-31 re-
introduction also significantly increases the surviving fraction
of NCI-H2452 cells treated with carboplatin (p = 0.0073), and
suppression of miR-31 significantly increases sensitivity to
carboplatin using IC50 doses (p = 0.0198) (n = 3). The dashed
line represents cells treated with vehicle control (PBS).
(B) Assaying cumulative proliferation with cisplatin treatment
revealed a significant decrease in proliferation at all time
points in miR-VC cells, whereas miR-31 cells appear less
sensitive to the chemotherapeutic agent. The reintroduction
of miR-31 in NCI-H2452 cells alters cellular proliferation in
response to cisplatin treatment. NCI-H2452 miR-VC cells
treated with 1 mM cisplatin have a significant difference in
proliferation compared to NCI-H2452 miR-VC untreated
cells at day 3 (p = 0.0027), day 6 (p = 0.0366), and day 9
(p = 0.0191) (n = 3). There is no significant difference (ns)
between the NCI-H2452 miR-31 cells treated with 1 mM
cisplatin until day 9 (p = 0.0306) and the untreated equivalent
(n = 3). Data are presented as the mean ± SEM. *p < 0.05;
**p < 0.01.
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cellular resistance to chemotherapy, miR-31 altered uptake or efﬂux
of chemotherapeutics was investigated. Surprisingly, the intracellular
level of platinumwas increased in NCI-H2452 cells reconstituted with
miR-31 (Figure 3). Studies have implicated the importance of inﬂux
and efﬂux of drugs in chemoresistance,29,30 which directed us to
investigate cisplatin ﬂux. No statistically signiﬁcant differences in
the expression of the efﬂux proteins ATP7A and ATP7B were ascer-
tained (Figure S8); however, there appeared to be a trend (p = 0.0722)
toward increased expression of CTR1 (Figure 4), a copper transporter
known to facilitate inﬂux of cisplatin into the cell.31 This increase in
inﬂux could explain, at least partly, the increased overall concentra-
tion of platinum in the miR-31-expressing cells, yet this did not
explain the observed resistant phenotype and attenuated DNA dam-
age. Previously, oxidant and antioxidant levels have been linked to
resistance to treatment and detoxiﬁcation of platinum-based thera-
pies.32,33 To determine whether oxidant and antioxidant levels
contributed to resistance, reactive oxygen species (ROS) generation
and glutathione levels were assessed. There were no signiﬁcant
changes between vector control and miR-31-expressing cells (Fig-
ure S7), indicating that miR-31-enhanced chemoresistance is largely
independent of ROS biology.
miR-31 Modulates Nuclear Accumulation of Cisplatin
To further attempt to determine how miR-31-expressing MPM cells
remained resistant despite an increase in the level of intracellularcisplatin, subcellular fractionation was employed to separate the
organelles of the cells and determine the platinum burden in each
fraction. The nuclear fraction was collected and analyzed via induc-
tively coupled plasma mass spectrometry (ICP-MS) to determine
whether there was a difference in accumulation of platinum in the nu-
clear region, where it would be expected to promote cross-linking
damage. There was a decrease by approximately 50% in nuclear accu-
mulation of cisplatin observed upon miR-31 re-expression in NCI-
H2452 cells (Figure 5B). In addition, the lysosomal fraction illustrated
a 0.28 ± 0.07 ppm increase in platinum concentration (Figure 5A).
The alterations in gH2A.X supported this ﬁnding, collectively
demonstrating that miR-31 regulates nuclear transport, whereby traf-
ﬁcking of cisplatin to the nucleus is reduced. This limits damage to
DNA indicative of chemotherapeutic treatment, ultimately confer-
ring a survival advantage.
To explain the observed more resistant phenotype, despite a greater
concentration of platinum within the cellular environment and less
accumulation within the nuclear region, the literature was thoroughly
reviewed. There are many routes by which accumulation within the
cellular environment may be facilitated, including the efﬁciency of
exosome packaging of cisplatin,34 changes in the structure of the nu-
clear region,35 rearrangements of cytoskeletal components,36 and
lysosomal transport.24 Established links have been found among
miR-31 expression, resistance to therapy, and the lysosomally bound
drug transporter ABCB9.37,38Molecular Therapy: Nucleic Acids Vol. 8 September 2017 319
Figure 2. The Expression of miR-31 Correlates with the Amount of DNA Damage Incurred when Treated with Platinum-Based Chemotherapeutics
(A) Representative western blot time course for gH2A.X as a marker of DNA damage with cisplatin treatment (50 mM). Across all time points, it is evident that levels of gH2A.X
decreased in miR-31-positive cells. (B) Representative western blot for gH2A.X with cisplatin treatment (50 mM). The confirmation of a reduction in DNA damage with miR-31
can be viewed in the second band (left to right), with an increase in DNA damage evident in the miR-31-suppressed P31 cell line. (C) Representative western blot for gH2A.X
with carboplatin treatment (500 mM).
Molecular Therapy: Nucleic Acids
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Figure 3. Intracellular Cisplatin Content Is Increased with miR-31
Reintroduction
ICP-MS analysis of NCI-H2452 and P31-transfected cell lines treated with 50 mM
cisplatin for 24 hr. There is a significant (p = 0.0112) increase in the levels of platinum
in NCI-H2452 miR-31 cells compared to miR-VC equivalent, but there is no change
in overall platinum levels with miR-31 suppression (n = 3). Data are presented as the
mean ± SEM. *p < 0.05; **p < 0.01; ns, not significant.
www.moleculartherapy.orgLysosomally Bound ABCB9 Is Upregulated with miR-31
Re-expression in MPM Cells, Potentially via an OCT1-Mediated
Mechanism in the Extranuclear Compartment
With an increase in overall concentration of cisplatin, increased drug
inﬂux, and reduced nuclear accumulation of the drug, the potential
capability of miR-31-expressing cells to sequester cisplatin into cyto-
solic organelles within the cell was investigated. One route by which
cells can sequester cytotoxic drugs from the nucleus is through pack-
aging into intracellular vesicles such as lysosomes.23 An association
between miR-31 and the lysosomally bound transporter ABCB9 had
been previously established in non-small cell lung cancer (NSCLC),38
thus prompting an investigation as to whether miR-31 may modulate
ABCB9 expression in MPM cells, which consequently may regulate
cisplatin transport across the lysosomal membrane. Here, it was iden-
tiﬁed that there was an upregulation of ABCB9 at both the gene (Fig-
ure 6A) and the protein (Figures 6B and 6C) level upon reintroduction
of miR-31. This was supported by immunoﬂuorescent studies exam-
ining intracellular ABCB9 localization (Figures 6D and 6E). To estab-
lish whether the change in ABCB9 expression was accounted for by an
increase in the overall burden of lysosomes within the miR-31-ex-
pressing cells, the expression of the lysosomal marker LAMP1 was
analyzed. It was established that there were no changes in LAMP1
expression, as determined by immunoﬂuorescence and western blot,
supporting a speciﬁc upregulation of the ABCB9 transporter rather
than an increase in the density of lysosomes in the NCI-H2452
miR-31-expressing cell population (Figures 6B–6D and 6F).
Because the mechanism of action for miRNAs typically involves the
negative regulation of target genes at the post-transcriptional level,
the observed upregulation of ABCB9 upon miR-31 reintroductionindicated the activity of a potential intermediate negative regulator
of ABCB9 expression. Here, bioinformatic tools were used to identify
potential negative transcriptional regulators of ABCB9, which may be
altered by miR-31 (Figure S10; Table S1). OCT1 has previously been
noted as a bipotential transcription factor,22 which we propose,
within our system, is a negative regulator of abcb9 transcription. In
line with the present model, it was observed that there was a concom-
itant reduction in OCT1 expression upon miR-31 reintroduction into
NCI-H2452 cells (Figure 7). This may connote miR-31 targeting
OCT1, facilitating the increased transcription of downstream pro-
teins such as CTR1 and ABCB9, both of which have binding sites
for OCT1.
Direct ABCB9 Overexpression Promotes Chemosensitivity of
MPM Cells, Independent of miR-31 Expression
With a correlation between miR-31 reintroduction and ABCB9 over-
expression possibly modulating the intracellular accumulation of
platinum-based therapy, independent overexpression of ABCB9
was performed in the miR-31 null NCI-H2452 cell line (Figure S11).
Surprisingly, overexpression of ABCB9 led to greater levels of
gH2A.X induction, suggesting that the high ABCB9-expressing
clones (C2 and C3) may be more chemosensitive (Figure 8A). Sup-
porting this, when the clonogenic capacity of the ABCB9-overex-
pressing NCI-H2452 cells was assessed with a clinically relevant
dose of cisplatin, a signiﬁcantly more chemosensitive phenotype
was displayed. The NCI-H2452 ABCB9 overexpressing population
had a surviving fraction of 64 ± 19, compared to 93 ± 9 in the vector
control (termed EX-NEG) population, meaning ABCB9-overexpress-
ing cells were on average 29% more sensitive than the vector control
equivalent (Figure 8B).
In addition, as a measure of cisplatin-induced DNA damage, gH2A.X
induction was signiﬁcantly reduced in NCI-H2452 cells with co-over-
expression of ABCB9 and miR-31 (Figure 8A). This indicates that
ABCB9 overexpression in the presence of miR-31 is not sufﬁcient
to confer a chemosensitive phenotype, thereby inferring that while
miR-31 expression promotes ABCB9 expression, the miR-31-medi-
ated chemoresistant phenotype is independent of ABCB9.
DISCUSSION
It is apparent that the role of miR-31 within differing tumor types is
multi-faceted and its exact functions remain unclear, with context-
dependent evidence supporting both oncogenic and tumor-suppres-
sive functions.18,39,40 Within MPM, deletion of the fragile site at
which miR-31 is encoded has been correlated with poor prognosis;17
however, it has also been reported that miR-31 expression is allied
with aggressive tumor subtypes in patient cohorts.19 Surprisingly,
the present study has determined that miR-31 expression in MPM
promotes resistance to platinum-based therapy in vitro. However,
the suppression of miR-31 in the P31 cell line led to no signiﬁcant dif-
ference in the surviving fraction when treated with carboplatin. Car-
boplatin relies upon passive diffusion to enter the cell;41 hence, poten-
tial pleiotropic alterations due to the suppression of miR-31 may
modulate the ability of the molecule to enter the cellular environment.Molecular Therapy: Nucleic Acids Vol. 8 September 2017 321
Figure 4. miR-31 Rehabilitation in MPM Cells
May Alter the Expression of Drug Influx
Transporter CTR1
(A) Expression levels of drug influx transporter slc31a1
(CTR1) were analyzed via qPCR. Relative quantity (RQ)
relates to relative fold change (n = 4). (B) Representative
western blot illustrating CTR1 expression to bemoderately
amplified by miR-31 reintroduction. (C) Densitometry
analysis revealing upregulation of the CTR1 protein (n = 3).
Data are presented as the mean ± SEM.
Molecular Therapy: Nucleic AcidsData from this study indicate the loss of miR-31 in MPM tumors may
confer a chemosensitive phenotype. Although the data represented
here are in in vitro-based 2D models, there may be allied results
in vivo. In contrast to the initial hypothesis, the data support the alter-
native hypothesis that miR-31 loss in MPM confers a positive prog-
nostic inﬂuence. The potential mechanism by which miR-31 appears
to mediate resistance relies upon regulation of intracellular transport.
Dependence upon nuclear transport has previously been noted in
breast cancer,42 with associations between altered transport of plat-
inum-containing agents within the cellular environment and resis-
tance to therapy being comprehensively reviewed.43 Laurila et al.44
detailed the involvement of a nuclear transport protein, KPNA7,
with promotion of malignancy in pancreatic cancer. The silencing
of KPNA7 led to the inhibition of malignancy in pancreatic cell lines,
which highlights the importance of transportation from the cyto-
plasmic to the nuclear compartment and its involvement with resis-
tance to therapy.
Cellular accumulation of chemotherapeutics has been comprehen-
sively reviewed.45 With a higher overall amount of platinum in
miR-31-expressing cells (Figure 3) and a reduction in the concentra-
tion of platinum in the nuclear fraction (Figure 5), the question re-
mained as to how cells were able to survive an increased intracellular
concentration of cisplatin. There is evidence supporting that miRNAs
can mediate cellular sequestration through the alteration of calcium
signaling or the mediation of multi-drug-resistant proteins.46–48
Here, following further fractionation of cellular components, a
change in lysosomal accumulation was observed; this promoted the322 Molecular Therapy: Nucleic Acids Vol. 8 September 2017investigation of possible drug transporters that
were bound to lysosomes and promoted the
investigation as to whether miR-31-expressing
cells had a higher aggregate burden of lyso-
somes. Pennati et al.47 showed that miR-205
replacement in prostate cancer cells downregu-
lated lysosome function and protein trafﬁcking,
leading to alterations in the autophagic ﬂux of
cells, which changed the detoxifying capabilities
by which cells become cisplatin resistant. Dray-
ton et al.49 correlated reduced miR-27a expres-
sion with the cysteine and glutamate exchanger
SLC7A11. Cisplatin-resistant bladder cancer
cell lines were resensitized by initiating miR-27a expression, or reducing the activity of SLC7A11 via siRNA, which
supports the ﬁndings that miRNAs can regulate cellular transporters,
thus connoting regulation of cellular chemoresistance.
The lysosomally bound drug transporter ABCB937 has been identi-
ﬁed as a modulator of resistance, with up- or downregulation of the
protein enhancing or reducing response to therapeutics.50 Surpris-
ingly, while ABCB9 appears to be increased with the miR-31 over-
expressing more resistant phenotype, upon manipulation of ABCB9
in miR-31 null NCI-H2452 cells, there is a sensitizing effect to
cisplatin treatment. Dong et al.38 examined the relationship between
miR-31 and ABCB9. The investigation established a link in NSCLC
cisplatin resistant cell lines having higher expression of miR-31,
with a downregulation of the drug transporter ABCB9, potentiating
that miR-31 directly targeted ABCB9 and so repressed its transla-
tion. However, there is an elevation in ABCB9 protein associated
with the miR-31-mediated chemoresistant phenotype. Contextually,
this may be explained by the pleiotropic function of microRNAs,
including miR-31 targeting the mRNA of a transcription factor
that regulates ABCB9. In short, the increase of miR-31 expression
may lead to a downregulation of a potential negative regulator of
transcription, effectively taking off a transcriptional brake, which
may lead to an increase in the expression of target proteins such
as ABCB9. Here, we potentially identiﬁed OCT1 as a candidate
for such a theory. Dong et al.38 also focused upon the inhibition
of ABCB9 contributing to cisplatin resistance in NSCLC, and our
reciprocal ABCB9-overexpression data in MPM supports these pre-
vious ﬁndings.
Figure 5.miR-31 Status Affects the Cisplatin Content of SpecificOrganelles
within the Intracellular Environment
(A) Isolation of the lysosomal fraction following 50 mM cisplatin treatment for 24 hr
illustrated a trend toward increased cisplatin concentration with miR-31 re-
introduction; however, this is not significant (ns = not significant) (n = 3). (B) ICP-MS
analysis indicated a significant difference (p = 0.0028) in platinum concentration
within the nuclear fraction of miR-31-expressing cells following 50 mM cisplatin
treatment for 24 hr. A trend toward an increased concentration within the miR-31-
suppressed population is evident (n = 3). Data are presented as the mean ± SEM.
*p < 0.05; **p < 0.01.
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within in vitro studies of MPM, with an observed increase in
ABCB9 expression. However, when ABCB9 is overexpressed inde-
pendently of miR-31, an increase in sensitivity is observed, opposing
the initial hypothesis and perhaps indicating that the increase in
ABCB9 is passive, because miR-31 is mediating other molecules
that potentially contribute more to the regulation of cisplatin intracel-
lular accumulation. This implies that ABCB9 expression is important
within the context of MPM; however, ABCB9 upregulation, in this
case, does not contribute to the speciﬁc pathway mediated by
miR-31 to enhance MPM chemoresistance. Although the alteration
in sensitivity to cisplatin with ABCB9 overexpression was apparent,there can be limitations to the signiﬁcance of this observation when
the analysis of the model used is completed. As in Figure S12, the
miR-31-driven and miR-31-independent overexpression of ABCB9
led to differing localization of the transporter within the cellular envi-
ronment, which may explain the differing response observed.
The movement of platinum-based chemotherapeutics within the
intracellular environment is widely characterized, with CTR1,
ATP7A, and ATP7B known to play signiﬁcant trafﬁcking roles.51,52
Although no signiﬁcant changes are apparent for the inﬂux and efﬂux
transporters CTR1 (Figure 3), ATP7A, and ATP7B (Figure S8), there
may be contributions to the overall phenotypic resistance observed
with miR-31 reintroduction. Stordal et al.53 and Kalayda et al.54 illus-
trated the importance of localization of these key proteins, which
can modulate accumulation and orchestrate the sequestration of
cisplatin within resistant cells, although there is typically no change
in overall expression. ATP7A and ATP7B have been established as
Golgi network transporters; however, within resistant models, a
translocation to outer vesicular structures has been noted,54 signifying
that while the present results show no gross difference, these mole-
cules may be modulating sensitivity through alterations in their
localization.
The effect of miR-31 reintroduction on increasing chemoresistance
was in agreement with our initial hypothesis; however, the group
had previously associated miR-31 overexpression with increased
sensitivity to therapy in esophageal adenocarcinoma.18 Although
unanticipated, a potentially novel mechanism behind enhanced resis-
tance, which may potentiate a modiﬁed strategy of treatment in the
future, has been uncovered. Many MPM patients are inherently resis-
tant to chemotherapy, and most have extremely poor prognosis; this
has driven the ﬁeld to ﬁnd an alternative therapeutic or enhance the
ability of the readily available therapeutics to combat this disease. Pro-
spectively, the consequence of further investigating this mechanism
within an in vivo system may lead to the ability to screen patients
for miR-31 status. Patients who express high levels of miR-31 could
be stratiﬁed to have an antagomir administered to suppress miR-31
expression, which could mean the efﬁciency of platinum-based
chemotherapy cytotoxicity would be enhanced. Zhang et al.55 co-
treated with both paclitaxel and antagomir miR-10b in breast cancer
cell lines, using the chemotherapeutic to treat the primary tumor and
suppressing miR-10b to decrease metastasis. The results were prom-
ising, and they concluded administration was successful for both the
antagomir and the paclitaxel via a liposomal-based system.
miRNA treatment in the form of nucleic acid-modiﬁed DNA phos-
phorothioate antisense oligonucleotides has already entered human
clinical trials in treatment of disease, although not in cancer. miR-
122, the abundant liver-expressed miRNA, is sequestered by the
oligonucleotide and bound in a duplex, which inhibits endogenous
function within hepatitis C virus infection. Results thus far have
shown promise, with long-standing dose-dependent decreases in
infection levels without evidence of acquired resistance.56 In relation
to mesothelioma, there has been progress in clinical trials usingMolecular Therapy: Nucleic Acids Vol. 8 September 2017 323
Figure 6. Reintroduction of miR-31 Affects Lysosomal Drug Transport
(A) Expression levels of the drug influx transporter abcb9 were analyzed via qPCR. There is a significantly greater relative expression level (p = 0.0251) of ABCB9 in miR-31-
transfected cells compared to the miR-VC-transfected equivalent (n = 4). RQ relates to relative fold change. (B) Representative western blot illustrating an increase in ABCB9
expression level with miR-31 re-expression, with no apparent change in the lysosomal marker LAMP1. (C) Densitometry analysis revealing significant (p = 0.0325) upre-
gulation of ABCB9 (n = 3). (D) Mean signal intensities of NCI-H2452-transfected cells immunofluorescently stained with ABCB9 or LAMP1, with intensities captured in the
Texas red channel for the images in (E). (E and F) Immunofluorescent images showing slight alteration in ABCB9 (E) or LAMP1 (F) staining (red); nuclei are stained with DAPI
(blue). Images were captured on LSM 710 with a 63/1.40 oil DICM27 objective for ABCB9 images and a 10/0.25 Ph1 objective for LAMP1 images. Data are presented as
the mean ± SEM. *p < 0.05; **p < 0.01.
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Figure 7. The Bipotential Transcriptional Regulator, OCT1, Can Be
Associated with miR-31 Expression
(A) Representative western blot illustrating the downregulation of a potential nega-
tive regulator of both CTR1 and ABCB9 expression, OCT1, with miR-31 re-
introduction. Suppression of miR-31 does not affect expression of OCT1.
(B) Densitometry analysis of OCT1 expression with miR-31 reintroduction (NCI-
H2452) or miR-31 suppression (P31) (n = 2). The data demonstrate a large decrease
in OCT1 with miR-31 re-expression, potentiating miR-31-mediated downregulation
of OCT1 and leading to upregulation of CTR1 and ABCB9 expression. Data are
presented as the mean ± SEM.
Figure 8. Overexpression of the Lysosomal Drug Transporter ABCB9
Affects Chemosensitivity, Independent of miR-31
(A) Representative western blot demonstrating the increased levels of gH2A.X with
high expression of ABCB9 in the parent NCI-H2452 cell line (the ABCB9 over-
expression cell line is termed NCI-H2452 ABCB9+). Clones B2–B4 correlate to EX-
NEG vector control clones (vector control for ABCB9 overexpression model is
termed NCI-H2452 EX-NEG). Clones C2 and C3 correlate to high expressers of
ABCB9, and C4 is a low expresser of ABCB9. All clones were treated for 24 hr with
50 mM cisplatin. (B) ABCB9 overexpression sensitizes miR-31 null NCI-H2452 cells
to cisplatin after treatment with 1 mM cisplatin for 24 hr, with near significance
reached (p = 0.0516) (n = 3). Data are presented as the mean ± SEM.
www.moleculartherapy.orgmiRNAs to modulate the disease, Kao et al.57 reported both a meta-
bolic and radiological response with miR-16-based mimics. The
further development of TargomiRs, miRNAs delivered via bacterial
minicells, to treat thoracic cancers has also shown promise.58
Within the context of this study, miR-31 expression in MPM facili-
tates resistance to platinum-based chemotherapy. miR-31-mediated
changes in ABCB9 expression and lysosomal uptake of cisplatin are
not sufﬁcient to promote chemoresistance, indicating that miR-31
mediates chemoresistance inMPM through a yet-unidentiﬁed molec-
ular mechanism involving reduced nuclear trafﬁcking of chemother-
apeutic agents; however, the vector-driven overexpression may limit
the signiﬁcance of the ABCB9 arm in this investigation. Prospectively,
although not within the remit of the current investigation, this
research would beneﬁt from support within the in vivo setting with
the use of an MPM mouse model. In addition, data would be sup-
ported with MPM patient-derived samples with and without chemo-therapeutic treatment to analyze miR-31 status, and potentially OCT1
or ABCB9 expression; these aspects would strengthen the impact of
the current research. Our data suggest that while deletions in chromo-
some 9p21.3 may be associated with an overall poor prognosis, the
speciﬁc loss of miR-31 from this regionmay not contribute to the che-
moresistance observed in MPM patients. Screening patients for
miR-31 expression status and corresponding suppression of the
miRNA may promote enhanced sensitivity to platinum-based che-
motherapeutics, improving patient outcomes.
MATERIALS AND METHODS
Cell Culture
The MPM epithelioid subtype cell lines NCI-H2452 and P31 were
gifts from Dr. Steven Gray (Department of Oncology and Clinical
Medicine, Trinity Translational Medicine Institute, Trinity Sciences
Health Centre, St. James’s Hospital). Cell lines were maintained in
RPMI 1640 medium (Lonza) supplemented with 10% fetal bovine
serum (HyClone), 1% penicillin/streptomycin (Lonza), and 1%Molecular Therapy: Nucleic Acids Vol. 8 September 2017 325
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at 37C, 5% CO2. Regular mycoplasma testing was carried out using
the MycoAlert Mycoplasma Detection Kit (Lonza), with no contam-
ination evident.
Cytotoxic Reagents
Cisplatin was purchased from Acros Organics (Thermo Fisher Scien-
tiﬁc) and solubilized in sterile PBS (Lonza). Carboplatin was pur-
chased from Selleckchem (Stratech) and solubilized in sterile PBS
(Lonza). Aliquots were stored at 20C and thawed immediately
before use.
miRNA Transfection
Transfections were performed using Lipofectamine 2000 reagent
from Invitrogen according to the manufacturer’s instructions.
miR-31 overexpression plasmid (MI0000089) and vector control
(PCMVMIR) were purchased from Origene and stably transfected
into the NCI-H2452 cell line under 500 mg/mL G418 (Thermo Fisher
Scientiﬁc) selection for 21 days. Zip-miR-31 plasmid (MZIP31-
PA-1) and Zip vector control (MZIP000-PA-1) were purchased
from SBI and stably transfected into the P31 cell line under
3 mg/mL puromycin (Sigma Aldrich) selection for 10 days.
ABCB9 Transfection
Lipofectamine 2000 reagent from Invitrogen was used according to
the manufacturer’s instructions. ABCB9 (EX-T8156-M68) overex-
pression plasmid and vector control (EX-NEG-M68) were purchased
from GeneCopoeia and stably transfected into the NCI-H2452 cell
line under 2 mg/mL puromycin (Sigma Aldrich) selection for
14 days. The surviving cells were kept under 0.5 mg/mL puromycin
maintenance selection while culturing.
Clonogenic Assay
Clonal survival was determined by seeding NCI-H2452 (5  102–
1.5  103) or P31-transfected cells (5  102–1  103) into 6-well
plates and allowing them to adhere overnight. Cells were subjected
to cisplatin treatment using established doses (Figure S3) for 24 hr,
and then treatment was removed and complete RPMI was applied.
Plates were incubated for 8–10 days after seeding. Colonies were ﬁxed
and stained with crystal violet solution (0.1% w/v crystal violet,
70% v/v methanol, 30% v/v deionized water), and wells were washed
with water until colonies were distinct. Colonies were counted using
the Oxford Optronix GelCount instrument and optimized compact
hough and radial map (CHARM) image processing algorithms for
each cell line.
Plating efﬁciency was calculated as the colony count divided by the
number of cells seeded. Surviving fraction was therefore calculated
as the colony count divided by the plating efﬁciency of the control
and multiplied by the number of cells seeded.
Cumulative Proliferation Assay
A proliferation assay was employed wherein 3 105 cells were seeded
into 10 cm2 tissue culture dishes and allowed to adhere overnight.326 Molecular Therapy: Nucleic Acids Vol. 8 September 2017Cisplatin treatment was then applied for 24 hr. Cells were reseeded
at 3  105 every 3 days, for a total of 9 days, and a cumulative cell
count was taken.
ICP-MS
Cells were treated with 50 mM cisplatin for 24 hr, after which cells
were harvested and counted. Cells (1  106) were incubated in
HNO3 for 72 hr at room temperature, and following incubation,
HCl was added to each sample to form aqua regia at a ratio of 1:3,
ensuring total platinum was in solution. Samples were analyzed by
Perkin Elmer DRCII ICP-MS. Standard curves were generated using
aqueous serial dilutions of known standards. Each measurement
taken was representative of three technical replicates from an individ-
ual sample.
Subcellular Fractionation
Cells were subjected to homogenization using a sucrose-based solu-
tion (250 mM sucrose, 50 mM Tris-HCl, 5 mM MgCl2). Disruption
of the cellular membrane was completed with ﬁve strokes of a Dounce
homogenizer. Homogenized cells were then subjected to 600  g for
3 min to isolate nuclei; further fractionation at 6,000  g for 8 min
separated mitochondria, lysosomes, and peroxisomes.
Reverse Transcription and qPCR
Total RNA was isolated from cells using the RNeasy Mini kit
(QIAGEN) according to the manufacturers’ instructions. Quantiﬁca-
tion of total RNA, quality, and content was determined by Nanodrop
Lite (Thermo Fisher Scientiﬁc). RNA was reverse transcribed using
the QuantiTect Reverse Transcription kit (QIAGEN) according to
the manufacturers’ instructions. QuantiTect and the miScript SYBR
Green PCR Master mix (QIAGEN) were used to assess mRNA
and miRNA levels using real-time qPCR (Applied Biosystems).
Commercially available QuantiTect (CTR1, QT00099267; ABCB9,
QT00089047; ATP7A, QT00075852; and ATP7B, QT00075782)
and miScript (miR-31, MS00003290) primer assays were employed
for both the genes of interest and the endogenous controls (B2M,
QT00088935, for mRNA and RNU6, MS00033740, for miRNA).
Western Blot
Cells were lysed in cold radioimmunoprecipitation assay (RIPA)
buffer (50 mM Tris-HCl [pH 8], 1% Triton X, 0.5% sodium deoxy-
cholate, 0.1% SDS, 150 mM NaCl) with the addition of protease
and phosphatase inhibitor tablets (Pierce). Protein concentration
was quantiﬁed using the BCA protein assay kit (Pierce), with 50 mg
of protein per sample loaded onto gels. Proteins were separated on
7.5% or 10% SDS-PAGE gels, transferred onto polyvinylidene ﬂuo-
ride (PVDF) membrane (Thermo Fisher Scientiﬁc), and probed for
CTR1 (sc-66847) used at 1:1,000, ABCB9 (sc-393412) used at
1:1,000, LAMP1 (sc-17768) used at 1:1,000, OCT1 (sc-293181) used
at 1:1,000, b-actin (sc-130300) used at 1:10,000 (Santa Cruz Biotech-
nology), and gH2A.X (9718) used at 1:1,000 (Cell Signal), followed by
incubation with anti-mouse horseradish peroxidase (HRP)-conju-
gated secondary antibody (P0260) used at 1:2,000 (Dako) or anti-rab-
bit HRP-conjugated secondary antibody (sc-2004) used at 1:2,000
www.moleculartherapy.org(Santa Cruz Biotechnology). Bands were detected using Clarity west-
ern enhanced chemiluminescence (ECL) substrate (Bio-Rad) and
visualized using the ChemiDoc imaging system (Molecular Imager
ChemiDoc XRS with Image Lab 3.0). Densitometric analysis was per-
formed with Image Lab 3.0 software (Bio-Rad).
Nuclear Extraction
Cells were harvested and washed with ice-cold NEB buffer A
(10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 1 mM
DTT, protease inhibitor cocktail (PIC), ultrapure H2O) and pelleted
at 20,000  g for 2 min. Cells were washed a further two times with
NEB buffer A. Cell lysis was achieved by resuspending cells in NEB
buffer A plus 0.1% (v/v) NP40 with incubation on ice. Lysate was
separated by centrifugation at 20,000  g for 15 min, followed by
nuclear lysis with NEB buffer C (20 mM HEPES [pH 7.9],
1.5 mM MgCl2, 420 mM NaCl, 1 mM DTT, PIC, ultrapure H2O).
Insoluble material was removed via centrifugation at 20,000  g
for 15 min.
Immunofluorescence
NCI-H2452 miR-VC and NCI-H2452 miR-31 cell lines were seeded
on glass coverslips within a 6-well plate at a density of 4  105 per
well. Cells were ﬁxed with 4% formaldehyde and blocked with
blocking solution (1 PBS, 5% serum, 0.3% Triton X-100). Primary
antibody was applied in antibody dilution buffer (1 PBS, 1% BSA,
0.3% Triton X-100) and incubated at 4C overnight. Following
washing with 1 PBS, cells were incubated with Alexa Fluor 555
(Thermo Fisher Scientiﬁc) secondary antibody diluted in antibody
dilution buffer for 2 hr at room temperature. Coverslips were
reverse mounted onto glass slides with ProLong Gold Antifade
Mountant with DAPI (Thermo Fisher Scientiﬁc). Slides were left
to cure overnight before imaging on Zeiss LSM710 AxioObserver
Confocal microscope using the Plan Apochromat 63/1.40 oil
differential interference contrast (DIC) M27 objective for ABCB9
images and the LD A-Plan 10/0.25 Ph1 objective for LAMP1
images. Images were captured with AxioCamIC with a 0.5 camera
adapter.
Bioinformatics
Gene promoter bioinformatics analysis was performed using the
DECODE database (http://www.sabiosciences.com/chipqpcrsearch.
php?app=TFBS). Genes of interest were inserted, with analysis
showing the potential binding sites of more than 200 transcription
factors 20 kb upstream and 10 kb downstream of the gene.
Statistical Analysis
Data were statistically analyzed using InStat3 software. Unless other-
wise stated, data are presented as the mean ± SEM of three or more
independent experiments. Paired t test was performed on clonogenic
and ICP-MS data. Proliferation data were subject to analysis via
ANOVA with Tukey’s post hoc test. Densitometry and qPCR data
were analyzed for signiﬁcance using one-sample t test, wherein the
hypothetical mean was set to 1.0. Signiﬁcance was considered to be
p < 0.05.SUPPLEMENTAL INFORMATION
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